La radiación focal optimiza la terapia con paclitaxel en un modelo en ratones de cáncer mamario triple negativo


Maryland Rosenfeld Franklin, Thomas Dailey, and Wilbur R. Leopold



Encuentro Anual de AALAS

“Focal Radiation Enhances Paclitaxel Therapy in a Mouse Model of Triple Negative Breast Cancer”


Introduction & Background:

  • Triple negative breast cancer (TNBC) accounts for 15-20 % of all breast cancers in theUnited States.
  • Patients with TNBC have poorer prognosis and therapeutic intervention is more challenging due to insensitivity to
  • hormonal and anti-HER2 therapies.
  • Therapeutic options for TNBC can include chemotherapy and/or radiation (RT) treatment.
  • Clinical trials evaluating shorter, hypofractionated doses of radiation are being conducted in patients with breast cancer.
  • This study evaluated preclinical activity of paclitaxel in combination with either lower dose, more frequent radiation or higher dose, less frequent radiation.